What are the major results of the TIMI IIIB Trial?
The TIMI IIIB Trial demonstrated that thrombolytic therapy is effective for the treatment of unstable angina and non-Q-wave myocardial infarction. It also showed that glycoprotein IIb/IIIa receptor blockade with tirofiban improves outcomes in patients with acute coronary syndromes, and that early angioplasty in these patients can improve outcomes but may increase the need for repeat revascularization. Additionally, the trial found that glycoprotein IIb/IIIa receptor blockade with tirofiban improves outcomes in diabetic patients with acute coronary syndromes, and that intracoronary thrombus and glycoprotein IIb/IIIa receptor blockade with tirofiban can be effective in the treatment of unstable angina or non-Q-wave myocardial infarction. Finally, the trial found that the CASS and Pryor-Harrell-Lee scores can be used to estimate the likelihood of significant coronary artery disease.  